Sanofi (SNYNF)
| Market Cap | 129.74B |
| Revenue (ttm) | 45.85B |
| Net Income (ttm) | 5.76B |
| Shares Out | n/a |
| EPS (ttm) | 4.60 |
| PE Ratio | 22.54 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 160 |
| Average Volume | 12,808 |
| Open | 105.84 |
| Previous Close | 106.45 |
| Day's Range | 103.98 - 106.45 |
| 52-Week Range | 91.81 - 122.03 |
| Beta | 0.48 |
| RSI | 50.48 |
| Earnings Date | Apr 24, 2025 |
About Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; inf... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial numbers in EUR Financial StatementsNews
Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug
The pharmaceutical company said the profit was driven by a higher gross margin and slower operating expense growth.
Sanofi beats top-line and bottom-line estimates; reaffirms FY25 outlook
Sanofi's quarterly profit beats estimates on Dupixent boost, newer products
France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its anti-inflammatory drug Dupixent, as well as newer treatments and vaccines.
Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed
Sanofi: strong Q1 performance and 2025 guidance confirmed Paris, April 24, 2025 Q1 sales growth of 9.7% at CER 1 and business EPS 2 of €1.79 Pharma launches reached sales of €0.8 billion, up 43.8%, dr...
Novartis and Sanofi CEOs say EU should raise drug prices in face of tariffs
The European Union should allow drug prices to rise to U.S. levels in order to attract investment, the bosses of two European pharmaceutical giants said in a letter published in the Financial Times on...
Pharma bosses call for higher drug prices in EU to counter tariff threat
Novartis and Sanofi CEOs push for European benchmark against US prices
Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition
The U.S. Food and Drug Administration approved the extended use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with a type of skin condition, the two companies said on Friday.
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and...
Earendil Labs and Sanofi partner for two bispecific antibodies
Earendil Labs partners with Sanofi for AI-powered bispecific antibodies targeting autoimmune and bowel diseases. Read more here.
Sanofi Asthma Drug Misses Primary Goal, Plans For Pivotal Study
Sanofi SA (NASDAQ: SNY) on Tuesday shared progress from its mid- to late-stage respiratory pipeline . The French drug maker reported preliminary results from the TIDE-Asthma phase 2 study of amliteli...
Sanofi flunks mid-stage trial for asthma drug
Press Release: Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthma Lunsekimig...
Press Release: Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthma Lunsekimig...
How Do Investors Really Feel About Sanofi?
Sanofi's (NYSE: SNY) short percent of float has fallen 30.77% since its last report. The company recently reported that it has 4.00 million shares sold short , which is 0.18% of all regular shares th...
Global pharma shares plunge as Trump doubles down on tariff threat
Global drugmakers' stocks dropped across the board after U.S. President Donald Trump reiterated plans for a "major" tariff on pharmaceutical imports, threatening an interwoven global supply chain, and...
Europe’s pharma titans confront von der Leyen with threat to yank $113 billion from EU and relocate to U.S. as Trump plans ’major’ tariffs
Novo Nordisk and Sanofi were among companies threatening to hasten their exits to the U.S., as Trump promised pharma tariffs were coming 'shortly.'
Trump teases targeted tariffs on overseas drug manufacturers
With the next set of White House–imposed tariffs just hours away from taking effect — including the attention-hogging 104% rate to be levied on products from China as they're imported into the U.S. — ...
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in people...
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in people...
Why Is French Pharma Giant Sanofi Stock Trading Higher On Thursday?
The U.S. Food and Drug Administration (FDA) on Thursday granted orphan drug designation to Sanofi SA ‘s (NASDAQ: SNY) rilzabrutinib. The treatment is an investigational, novel, advanced, oral, revers...
Why Is French Pharma Giant Sanofi Stock Trading Higher On Thursday?
The U.S. Food and Drug Administration (FDA) on Thursday granted orphan drug designation to Sanofi SA‘s SNY rilzabrutinib.
Lamb Weston Posts Better-Than-Expected Results, Joins Sanofi And Other Big Stocks Moving Higher On Thursday
U.S. stocks were lower, with the Dow Jones index falling over 1,200 points on Thursday. Shares of Lamb Weston Holdings, Inc . (NYSE: LW) rose sharply during Thursday's session after the company repor...
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease Rilzabrutinib...